Since CXCR4 contributes to the survival of leukemic cells in the BMM, the combinatorial treatment of CXCR4 antagonists and FLT3 inhibitors may lead to improved therapeutic outcomes in AML. The gene discussed is FLT3; the disease is acute myeloid leukemia.